logo
Plus   Neg
Share
Email

Stock Alert: BioXcel Therapeutics Up 30%

Shares of BioXcel Therapeutics, Inc. (BTAI) are currently up nearly 30% on Monday morning trade after the company said that two late-stage trials of treatment for schizophrenia and bipolar disorder met their primary endpoints.

BTAI is currently trading at $67.83, up $14.84 or 28.01%, on the Nasdaq.

BioXcel Therapeutics is a clinical-stage biopharmaceutical company developing drugs utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.

BXCL501 was being evaluated in two phase III studies for the acute treatment of agitation in patients with schizophrenia, dubbed SERENITY I, and bipolar disorder, known as SERENITY II.

The company announced that BXCL501 met the primary and secondary endpoints of SERENITY I and SERENITY II, demonstrating a robust treatment effect in the trials.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
RELATED NEWS
Follow RTT